Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Medical Device Policy / Regulatory

China’s NMPA Issues Guidelines for Domestic Manufacturing of Imported Medical Devices

Fineline Cube Nov 5, 2024

The National Medical Products Administration (NMPA) has released a notification aimed at further clarifying the...

Company

Legend Biotech Corporation Appoints Alan Bash as President of Carvykti

Fineline Cube Nov 5, 2024

China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...

Company Deals

Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology

Fineline Cube Nov 5, 2024

Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...

Company Deals

Mirxes Holding Company Updates IPO Prospectus with 2024 Financials

Fineline Cube Nov 5, 2024

Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...

Company Deals

Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline

Fineline Cube Nov 5, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...

Company Medical Device

Shanghai HeartCare Medical Technology Receives NMPA Approval for Embolization Stent

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology...

Company Deals

Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments

Fineline Cube Nov 5, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center...

Company Drug

HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment

Fineline Cube Nov 5, 2024

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...

Company Medical Device

NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology...

Company Drug

Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging

Fineline Cube Nov 5, 2024

Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...

Company Drug

China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment

Fineline Cube Nov 5, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...

Company Digital

111 Inc. Appoints Yang “Luke” Chen to Board of Directors Following Resignation of Dr. Lian Yong Chen

Fineline Cube Nov 5, 2024

China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance...

Company Deals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan

Fineline Cube Nov 4, 2024

Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...

Policy / Regulatory

China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing

Fineline Cube Nov 4, 2024

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

Fineline Cube Nov 4, 2024

The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...

Company Medical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Fineline Cube Nov 4, 2024

US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...

Company Drug

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015

Fineline Cube Nov 4, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...

Company Drug

Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial

Fineline Cube Nov 4, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...

Company Deals

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing

Fineline Cube Nov 4, 2024

Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...

Company Medical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Fineline Cube Nov 4, 2024

China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...

Posts pagination

1 … 273 274 275 … 666

Recent updates

  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
  • China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Company

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.